Perspectives on the first randomized sham-controlled trial of stellate ganglion block for hot flashes

Pinkerton, JoAnn V.; Wilson, Carolyn S.

doi:10.1097/gme.0000000000000295

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 An RCT of 187 symptomatic menopausal women found that clinical hypnosis was associated with a 74.2% reduction in hot flushes, compared with a 17.1% reduction in women randomized to structured attention control (P < 0.001). 12 The effectiveness of acupuncture, 13 exercise, 14 yoga, 15 paced respiration, 16 relaxation training, 17 and mindfulness-based stress reduction 18 has not been established.…”

Section: Vasomotor Symptomsmentioning

confidence: 99%

Management of Menopausal Symptoms

Kaunitz

Manson

2015

Obstetrics &Amp; Gynecology

162

View full text Add to dashboard Cite

Most menopausal women experience vasomotor symptoms, with bothersome symptoms often lasting longer than one decade. Hormone therapy (HT) represents the most effective treatment for these symptoms, with oral and transdermal estrogen formulations having comparable efficacy. Findings from the Women’s Health Initiative and other recent randomized clinical trials have helped to clarify the benefits and risks of combination estrogen-progestin and estrogen-alone therapy. Absolute risks observed with HT tended to be small, especially in younger women. Neither regimen affected all-cause mortality rates. Given the lower rates of adverse events on HT among women close to menopause onset and at lower baseline risk of cardiovascular disease, risk stratification and personalized risk assessment appears to represent a sound strategy for optimizing the benefit: risk profile and safety of hormone therapy. Systemic HT should not be arbitrarily stopped at age 65; instead treatment duration should be individualized based on patients’ risk profiles and personal preferences. Genitourinary syndrome of menopause represents a common condition that adversely impacts the quality of life of many menopausal women. Without treatment, symptoms worsen over time. Low-dose vaginal estrogen represents highly effective treatment for this condition. Because custom-compounded hormones have not been tested for efficacy or safety, U.S. Food and Drug Administration (FDA)-approved HT is preferred. A low dose formulation of paroxetine mesylate currently represents the only nonhormonal medication FDA-approved to treat vasomotor symptoms. Gynecologists and other clinicians who remain abreast of data addressing the benefit: risk profile of hormonal and nonhormonal treatments can help menopausal women make sound choices regarding management of menopausal symptoms.

show abstract

Section: Vasomotor Symptomsmentioning

confidence: 99%

Management of Menopausal Symptoms

Kaunitz

Manson

2015

Obstetrics &Amp; Gynecology

162

View full text Add to dashboard Cite

show abstract

“…The pathogenesis of chronic ulcerative colitis is complex. However, recent studies have shown that this disease and immune dysfunction are correlated[ 41 , 42 ], and that the stellate ganglion block technique plays a very important role in regulating immune function[ 43 - 46 ]. Therefore, the main aim of this study was to investigate the efficacy and safety of the stellate ganglion block technique in the treatment of chronic ulcerative colitis.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

Zhao¹,

Yang²,

Sun³

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo investigate the efficacy and safety of stellate ganglion block for the treatment of patients with chronic ulcerative colitis.METHODSA total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital from January 2014 to January 2016 were included in this study. These patients were divided into two groups: control group (n = 30), patients received oral sulfasalazine treatment; experimental group (n = 90), patients received stellate ganglion block treatment. Clinical symptoms and disease activity in these two groups were compared before and after treatment using endoscopy. Blood was collected from patients on day 0, 10, 20 and 30 after treatment. Enzyme-linked immunosorbent assay was performed to determine interleukin-8 (IL-8) level. The changes in IL-8 level post-treatment in the two groups were compared using repeated measures analysis of variance.RESULTSAfter treatment, clinical symptoms and disease activity were shown to be alleviated by endoscopy in both the control and experimental groups. However, patients in the control group did not have obvious abdominal pain relief. In addition, the degree of pain relief in the experimental group was statistically better than that in the control group (P < 0.05). Ten days after treatment, IL-8 level was found to be significantly lower in the experimental group than in the control group, and the difference was statistically significant (P < 0.05). In addition, adverse events were significantly higher in the control group than in the experimental group, and the difference was statistically significant (χ2 = 33.215, P = 0.000).CONCLUSIONThe application of stellate ganglion block effectively improves treatment efficacy in chronic ulcerative colitis, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this approach also had a positive impact on the disease to a certain extent.

show abstract